We are live on
!
Find out more
CG
Carlyle Group Portfolio holdings
AUM
$10B
1-Year Est. Return
10.61%
This Fund
S&P 500
This Quarter
Est. Return
-16.38%
1 Year Est. Return
-10.61%
3 Year Est. Return
-7.98%
5 Year Est. Return
-20.78%
10 Year Est. Return
-1.56%
AUM
$1.05B
AUM Growth
-$533M
(-34%)
Cap. Flow
-$257M
Cap. Flow
% of AUM
-24.43%
Top 10 Holdings %
Top 10 Hldgs %
92.91%
Holding
33
New
1
Increased
–
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aon
AON
|
+$1.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GTM
ZoomInfo Technologies
GTM
|
+$126M |
| 2 |
VTRU
Vitru Limited Common Shares
VTRU
|
+$94M |
| 3 |
QuidelOrtho
QDEL
|
+$38.4M |
| 4 |
CFLT
Confluent
CFLT
|
+$234K |
| 5 |
Nu Holdings
NU
|
+$197K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.5% |
| 2 | Technology | 25.38% |
| 3 | Communication Services | 2.85% |
| 4 | Real Estate | 2.57% |
| 5 | Industrials | 1.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
QuidelOrtho
QDEL
$955M
| $383M | 36.35% |
11,520,751
-939,432
| -8% | -$38.4M |
|
|
GTM
2
ZoomInfo Technologies
GTM
$1.2B
| $220M | 20.91% |
17,244,747
-8,999,727
| -34% | -$126M |
|
|
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
| $166M | 15.8% |
4,071,562
| – | – |
|
4
GDS Holdings
GDS
$6.24B
| $37.8M | 3.59% |
4,072,624
| – | – |
|
5
Phathom Pharmaceuticals
PHAT
$732M
| $35.8M | 3.4% |
3,496,808
| – | – |
|
|
VRNA
6
DELISTED
Verona Pharma
VRNA
| $35.5M | 3.37% |
2,457,500
| – | – |
|
7
Getty Images
GETY
$97M
| $30M | 2.85% |
9,212,799
| – | – |
|
|
HLVX
8
DELISTED
HilleVax
HLVX
| $26.4M | 2.51% |
1,838,486
| – | – |
|
9
Jasper Therapeutics
JSPR
$22.8M
| $24.2M | 2.3% |
1,066,189
| – | – |
|
10
Q32 Bio
QTTB
$381M
| $19.2M | 1.82% |
1,102,741
| – | – |
|
11
SEACOR Marine Holdings
SMHI
$264M
| $17.7M | 1.68% |
1,314,164
| – | – |
|
12
Invitation Homes
INVH
$16.9B
| $17.1M | 1.63% |
477,500
| – | – |
|
13
CubeSmart
CUBE
$8.95B
| $9.96M | 0.95% |
220,500
| – | – |
|
14
SunPower Inc
SPWR
$83.9M
| $5.48M | 0.52% |
4,936,483
| – | – |
|
|
OKUR
15
OnKure Therapeutics
OKUR
$144M
| $4.16M | 0.39% |
269,896
| – | – |
|
|
EM
16
DELISTED
Smart Share Global Ltd
EM
| $4.13M | 0.39% |
4,810,209
| – | – |
|
17
Krispy Kreme
DNUT
$579M
| $3.67M | 0.35% |
340,748
| – | – |
|
18
Adicet Bio
ACET
$88.3M
| $3.6M | 0.34% |
184,295
| – | – |
|
|
SPRB
19
Spruce Biosciences
SPRB
$166M
| $1.52M | 0.14% |
38,620
| – | – |
|
|
20
Aon
AON
$69.4B
| $1.46M | 0.14% |
+4,973
| New | +$1.47M |
|
21
N-able
NABL
$754M
| $1.43M | 0.14% |
93,732
| – | – |
|
22
Broadcom
AVGO
$1.7T
| $1.21M | 0.12% |
7,550
| – | – |
|
|
SWI
23
DELISTED
SolarWinds Corporation Common Stock
SWI
| $1.13M | 0.11% |
93,735
| – | – |
|
|
24
Nu Holdings
NU
$75.7B
| $714K | 0.07% |
55,417
-16,924
| -23% | -$197K |
|
25
DoorDash
DASH
$96.2B
| $452K | 0.04% |
4,156
| – | – |
|
Similar funds
LA
NW
AC
BCM
OIAM
AI
AI
SWP
Carlyle Group's Q2 2024 Portfolio in Review
As of Q2 2024, Carlyle Group held 33 positions worth $1.05B, down 34% from $1.59B the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Carlyle Group withdrew a net $257M in Q2 2024, closing 2 positions and reducing 3 holdings. Its most notable exit was Vitru Limited Common Shares, an estimated $94M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 60% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Carlyle Group opened a new position in Aon worth $1.46M.
- Carlyle Group's largest Q2 2024 buy was Aon: 4,973 shares worth $1.46M.
- Carlyle Group's biggest Q2 2024 reduction was ZoomInfo Technologies, cutting an estimated $126M.
- Carlyle Group fully exited Vitru Limited Common Shares in Q2 2024, selling an estimated $94M.
- Carlyle Group's ten largest holdings make up 93% of its $1.05B portfolio in Q2 2024.
- Carlyle Group opened 1 new position and closed 2 in Q2 2024.
- Carlyle Group's portfolio value fell 34% quarter-over-quarter to $1.05B.
Based on Carlyle Group's 13F filing for Q2 2024, filed 9 Aug 2024.